These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 33673340)

  • 1. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JAMJL
    Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSHR as a therapeutic target in Graves' disease.
    Smith TJ
    Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-Like Growth Factor Pathway and the Thyroid.
    Smith TJ
    Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
    Fernando R; Caldera O; Smith TJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2021 update on thyroid-associated ophthalmopathy.
    Neag EJ; Smith TJ
    J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
    Smith TJ
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF1 receptor and thyroid-associated ophthalmopathy.
    Mohyi M; Smith TJ
    J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 16. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
    Smith TJ
    Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JA
    Front Endocrinol (Lausanne); 2016; 7():167. PubMed ID: 28096798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
    Fernando R; Smith TJ
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.